Highlights

• IDT Australia shares are trading 16.28% higher at AUD 0.050 during the 7 August 2026 session.

• FY26 revenue from the company's three core verticals is expected at AUD 16.8mn, up 16.5% year on year.

• FY26 EBITDA is expected to improve to a loss of about AUD 0.943mn.

• The company is focused on API manufacturing, specialty orals and advanced therapies.

IDT Australia Limited (ASX:IDT) is trading higher on Friday as the market revisits a turnaround that has become more measurable through upgraded FY26 guidance. The shares are up 16.28% at AUD 0.050 in the current intraday snapshot. Although turnover remains light, the operational backdrop has changed from earlier in the year, with management now expecting higher revenue and a materially narrower EBITDA loss as demand and cost savings feed through.

Company Overview

IDT Australia is a pharmaceutical manufacturing and development company with capabilities spanning active pharmaceutical ingredients, finished dose forms, sterile fill, specialty oral products and advanced therapies. Its facilities support contract development and manufacturing work across pharmaceutical and allied markets.

Recent Developments

On 21 July 2026, IDT upgraded its FY26 guidance. Revenue from its three core business verticals is expected to increase 16.5% year on year to AUD 16.8mn. EBITDA is forecast at a loss of approximately AUD 0.943mn, representing a significant improvement from prior periods. The upgrade followed an April outlook that had already pointed to a stronger finish to FY26, driven by demand, operating efficiencies and cost savings.

Turnaround Metrics Improve

The July guidance indicates that IDT is moving closer to breakeven after a multi-year programme to recommission facilities, realign resources and target higher-value manufacturing work. Earlier FY26 reporting showed growth in API manufacturing and specialty oral products, while management also increased its annualised cost-savings target. The company has highlighted opportunities across sterile fill, API manufacturing, radiopharmaceuticals and advanced therapies.

What to Watch

The next major checkpoint is the release of full-year results and audited accounts. The market will be looking for confirmation of the AUD 16.8mn revenue outcome, the expected EBITDA improvement and evidence that the stronger finish to FY26 can carry into FY27. New customer contracts and utilisation of recommissioned manufacturing capacity are also important.

Risks

IDT remains loss-making on an EBITDA basis under the latest guidance. Contract-manufacturing revenue can be affected by customer timing, project concentration and facility utilisation. The company must also maintain quality and regulatory compliance across pharmaceutical manufacturing operations while managing capital needs.